Research programme: kinase inhibitors - Daiichi Sankyo/Teva

Drug Profile

Research programme: kinase inhibitors - Daiichi Sankyo/Teva

Alternative Names: CEP-17940; CEP-18050; CEP-28122; CEP-31933; CEP-40783; CEP-4416; CEP-7055; CEP-A; RXDX-106

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Ambit Biosciences Corporation; Cephalon
  • Developer Daiichi Sankyo Company; Teva Pharmaceutical Industries
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Axl receptor tyrosine kinase inhibitors; Proto oncogene protein b raf inhibitors; Proto oncogene protein c met inhibitors; Proto-oncogene protein c-mer inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 29 Nov 2016 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 29 Nov 2016 Pharmacodynamic and Immunogenicity data from a preclinical trial presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016 )
  • 14 Mar 2016 Ignyta has patent protection for RXDX 106 in USA (Ignyta 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top